Serum Institute of India has already produced around 50 million dosages of the Oxford-AstraZeneca COVID-19 vaccine ''Covishield'' and plans to scale it up to 100 million by March next year even as it awaits approval for emergency use authorisation, a top company official said on Monday. The company, which has launched the country’s first indigenously developed pneumococcal vaccine – PNEUMOSIL- …